By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Centocor, Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 610-651-6000 Fax: 610-651-6100

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Centocor products have also saved lives in the treatment of heart attacks and have been used to reduce risk of cardiac events in interventional cardiology.

Centocor continues to pioneer new pathways in biomedical research and development. Drug discovery and development efforts focus on the following therapeutic areas: I.M.I.D. (Immune Mediated Inflammatory Diseases) hematology/oncology, infectious diseases, metabolic diseases, inflammatory bowel disorders, pulmonary disorders, central nervous system disorders, dermatology, rheumatology and cardiovascular disease. Centocor is looking for novel approaches that address the pathology of these diseases.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson, a worldwide manufacturer of healthcare products.


REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both rheumatoid arthritis (RA) and Crohn's disease (CD) in North America, the European Union (EU) and Japan. In the EU and in the U.S., REMICADE is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis.

Senior Officers:
Julie McHugh, President

Last Updated: 07-13-05

Key Statistics

Ownership: Subsidiary

Web Site: Centocor, Inc.
Employees: 3,133 worldwide (1Q 2003)
Symbol: JNJ


Company News
Centocor, Inc. (JNJ) Acquires RespiVert Ltd., Strengthens Pulmonary Focus 6/1/2010 6:36:15 AM
Edison Pharmaceuticals, Inc. Licenses Drug from Centocor, Inc. (JNJ) for Rare Diseases 1/5/2010 10:39:27 AM
FDA Extends Review of Centocor, Inc. (JNJ) (JOBS) Psoriasis Drug 5/27/2009 7:34:18 AM
Why Drug Companies Prefer Twitter Over Blogs; AstraZeneca PLC (AZN), Johnson & Johnson (JNJ), Centocor, Inc. (JNJ), and GlaxoSmithKline (GSK) Reviewed 5/20/2009 7:23:55 PM
Centocor, Inc. (JNJ)'s Psoriasis Drug May Ease Psoriatic Arthritis, Tufts University Study 2/13/2009 7:07:09 AM
Crucell N.V. (CRXL) Announces STAR(R) Research and Commercial License Agreement with Centocor, Inc. (JNJ) 1/6/2009 11:29:39 AM
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. (JNJ) 1/6/2009 6:44:57 AM
MorphoSys AG Announces Second Clinical Milestone in Therapeutic Antibody Program 12/11/2008 10:46:36 AM
GeneNews (GEN.TO) Provides Centocor, Inc. (JNJ) Access to its Osteoarthritis Program 12/11/2008 6:42:23 AM
MEDVERSATION(TM) Website Launched by Centocor, Inc. (JNJ) to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 11/12/2008 9:22:09 AM